Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
danazol + prednisone
- Development stage
- Unknown
- Lead developer
- Winthrop Company
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of danazol (a synthetic steroid with antigonadotropic and anti-estrogenic activities) and prednisone (a corticosteroid). This combination is primarily used in the treatment of primary myelofibrosis (PMF) and anemia, with or without red blood cell transfusion dependence. The combination has shown improved efficacy compared to either component alone, with studies demonstrating better response rates and prolonged response duration in patients with PMF and anemia.
02
Targets
ER (Estrogen receptor)GR (Glucocorticoid receptor)PR (Progesterone receptor)SERPINA6 (Corticosteroid-binding globulin)AR (Adrenergic receptors)
Beyond the preview
Go deeper on danazol + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on danazol + prednisone.